These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 6993490)

  • 1. Prostatic carcinoma: aspects of pathology, prognosis, and therapy.
    Kastendieck H
    J Cancer Res Clin Oncol; 1980; 96(2):131-56. PubMed ID: 6993490
    [No Abstract]   [Full Text] [Related]  

  • 2. Progress in pathology of carcinoma of prostate.
    Mostofi FK; Sesterhenn IA; Davis CJ
    Prog Clin Biol Res; 1987; 243A():445-75. PubMed ID: 3309974
    [No Abstract]   [Full Text] [Related]  

  • 3. A pathologist's view of prostatic carcinoma.
    Mostofi FK; Sesterhenn IA; Davis CJ
    Cancer; 1993 Feb; 71(3 Suppl):906-32. PubMed ID: 7679044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of prostatic intraepithelial neoplasia.
    Bostwick DG
    Mayo Clin Proc; 1995 Apr; 70(4):395-6. PubMed ID: 7898149
    [No Abstract]   [Full Text] [Related]  

  • 5. [Modern trends in the treatment of prostatic carcinoma].
    Atanasov N; Ianakieva M; Chakurov S; Bakurdzhiev T
    Khirurgiia (Sofiia); 1978; 31(5):392-8. PubMed ID: 83423
    [No Abstract]   [Full Text] [Related]  

  • 6. Continued targeting of androgen receptor signalling: a rational and efficacious therapeutic strategy in metastatic castration-resistant prostate cancer.
    Bianchini D; de Bono JS
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S189-94. PubMed ID: 21943974
    [No Abstract]   [Full Text] [Related]  

  • 7. Pathology of prostatic intraepithelial neoplasia and adenocarcinoma of the prostate: prognostic influences of stage, tumor volume, grade, and margins of resection.
    Epstein JI
    Semin Oncol; 1994 Oct; 21(5):527-41. PubMed ID: 7939746
    [No Abstract]   [Full Text] [Related]  

  • 8. [Recent data about prostatic carcinoma (author's transl)].
    Coune A
    Rev Med Brux; 1980 May; 1(5):311-4. PubMed ID: 7466030
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of Advanced Prostate Carcinoma - an Interdisciplinary Recommendation].
    Omlin A; Spahn M; Beyer J; Eberli D; Gillessen S; Jochum W; Kueng M; Nitzsche E; Rentsch CA; Roggero E; Schmid HP; Stenner F; Templeton AJ; Wild D; Wyler S; Zwahlen D; Cathomas R
    Praxis (Bern 1994); 2018 Sep; 107(19):1043-1051. PubMed ID: 30227804
    [No Abstract]   [Full Text] [Related]  

  • 10. Artificial neural networks for prostate carcinoma risk assessment. An overview.
    Montie JE; Wei JT
    Cancer; 2001 Apr; 91(8 Suppl):1647-52. PubMed ID: 11309763
    [No Abstract]   [Full Text] [Related]  

  • 11. Prostatic cancer--what to do? Staging and prognostic factors in the primary therapy decision.
    Faul P
    Eur Urol; 1992; 22(2):89-98. PubMed ID: 1478236
    [No Abstract]   [Full Text] [Related]  

  • 12. Node-positive prostatic carcinoma.
    Lawton C
    Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):671-2. PubMed ID: 9336148
    [No Abstract]   [Full Text] [Related]  

  • 13. Metastatic large-cell neuroendocrine prostate carcinoma: successful treatment with androgen deprivation therapy.
    Azad AA; Jones EC; Chi KN
    Clin Genitourin Cancer; 2014 Aug; 12(4):e151-3. PubMed ID: 24787970
    [No Abstract]   [Full Text] [Related]  

  • 14. [Diagnosis and treatment of early prostate cancer].
    Kaprin AD; Khalil Farzat M; Gafanov RA; Kostin AA
    Vopr Onkol; 2009; 55(3):382-5. PubMed ID: 19670743
    [No Abstract]   [Full Text] [Related]  

  • 15. [The T1 stage in prostatic carcinoma: incidence, morphologic characteristics, therapy and prognosis].
    Kliment J; Beseda A; Mikulás J
    Bratisl Lek Listy; 1988 Jan; 89(1):20-3. PubMed ID: 3359337
    [No Abstract]   [Full Text] [Related]  

  • 16. [Combined androgen blockade for prostate cancer].
    Shimazui T
    Nihon Rinsho; 2016 May; 74 Suppl 3():578-83. PubMed ID: 27344797
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapy of prostatic carcinoma and follow-up control (II)].
    Alken CE; Dhom G; Straube W; Schmidt-Hermes HJ; Moormann JG; Moeller JF
    Urologe A; 1973 Jul; 12(4):191-7. PubMed ID: 4726451
    [No Abstract]   [Full Text] [Related]  

  • 18. Identification of intermediate-risk prostate cancer patients treated with radiotherapy suitable for neoadjuvant hormone studies.
    Duchesne GM; Bloomfield D; Wall P
    Radiother Oncol; 1996 Jan; 38(1):7-12. PubMed ID: 8850420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testosterone measurement in patients with prostate cancer.
    Schulman CC; Irani J; Morote J; Schalken JA; Montorsi F; Chlosta PL; Heidenreich A
    Eur Urol; 2010 Jul; 58(1):65-74. PubMed ID: 20434831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [What is safe in the therapy of advanced prostatic cancer?].
    Gropp C; Burk K
    Internist (Berl); 1985 Dec; 26(12):765-70. PubMed ID: 3936819
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.